{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:24Z","timestamp":1786980564577,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10147-015-0832-5","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T13:14:48Z","timestamp":1431522888000},"page":"1102-1109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Kenichi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumasa","family":"Kuroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Armour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutsuna","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"832_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320\u2013368","journal-title":"Oncologist"},{"key":"832_CR2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","volume":"353","author":"HJ Burstein","year":"2005","unstructured":"Burstein HJ, Winer EP (2005) The distinctive nature of HER2 positive breast cancer. N Engl J Med 353:1652\u20131654","journal-title":"N Engl J Med"},{"key":"832_CR3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","volume":"32","author":"SH Giordano","year":"2014","unstructured":"Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2\u2013positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078\u20132099","journal-title":"J Clin Oncol"},{"key":"832_CR4","unstructured":"National comprehensive cancer network (2014) Clinical practice guidelines in oncology. Breast cancer. Version 3"},{"key":"832_CR5","unstructured":"Japanese Breast Cancer Society (2013) Evidence based breast cancer diagnostic guideline. Japanese Breast Cancer Society, editors. 1 Medicinal Therapy. 2013 version. Tokyo: Kanehara Shuppan, Tokyo"},{"key":"832_CR6","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977","journal-title":"Cancer"},{"key":"832_CR7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6601970","volume":"91","author":"AJ Clayton","year":"2004","unstructured":"Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639\u2013643","journal-title":"Br J Cancer"},{"key":"832_CR8","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","volume":"13","author":"NU Lin","year":"2007","unstructured":"Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648\u20131655","journal-title":"Clin Cancer Res"},{"key":"832_CR9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.breast.2005.04.017","volume":"15","author":"HJ Stemmler","year":"2006","unstructured":"Stemmler HJ, Kahlert S, Siekiera W et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219\u2013225","journal-title":"Breast"},{"key":"832_CR10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/02841860500486630","volume":"45","author":"T Yau","year":"2006","unstructured":"Yau T, Swanton C, Chua S et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196\u2013201","journal-title":"Acta Oncol"},{"key":"832_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2012.09.008","volume":"22","author":"DL Nielsen","year":"2013","unstructured":"Nielsen DL, Kumler I, Palshof AE et al (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22:1\u201312","journal-title":"Breast"},{"key":"832_CR12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"C Geyer","year":"2006","unstructured":"Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"832_CR13","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2\u2013positive breast cancer. J Clin Oncol 26:1993\u20131999","journal-title":"J Clin Oncol"},{"key":"832_CR14","doi-asserted-by":"crossref","unstructured":"Jones SF, Hainsworth JD, Spigel DR, et al (2004) A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 22(14S): (Abstract 2083)","DOI":"10.1200\/jco.2004.22.14_suppl.2083"},{"key":"832_CR15","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","volume":"26","author":"A Leo Di","year":"2008","unstructured":"Di Leo A, Gomez HL, Aziz Z et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544\u20135552","journal-title":"J Clin Oncol"},{"key":"832_CR16","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","volume":"31","author":"Z Guan","year":"2013","unstructured":"Guan Z, Xu B, DeSilvio ML et al (2013) Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2\u2013overexpressing metastatic breast cancer. J Clin Oncol 31:1947\u20131953","journal-title":"J Clin Oncol"},{"key":"832_CR17","doi-asserted-by":"crossref","unstructured":"Gelmon KA, Boyle F, Kaufman B, et al (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2\u00a0+\u00a0metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31\/GSK EGF 108919. J Clin Oncol 30 (suppl):LBA671","DOI":"10.1200\/jco.2012.30.18_suppl.lba671"},{"key":"832_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"832_CR19","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","volume":"32","author":"T Satoh","year":"2014","unstructured":"Satoh T, Xu RH, Chung HC et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study. J Clin Oncol 32(19):2039\u20132049","journal-title":"J Clin Oncol"},{"key":"832_CR20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0832-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-015-0832-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0832-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T21:48:19Z","timestamp":1566683299000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-015-0832-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0832-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}